Among 16 clinical trials included in this study, 9 clinical trials evaluated outcomes from 7 different antihypertensive regimen in CKD patients with diabetes: ACEI monotherapy, ARB monotherapy, ACEI-based spironolactone, ARB-based spironolactone, ARB and ACEI combination, and ARB-based renin inhibitor. The gene discussed is REN; the disease is chronic kidney disease.